Cardiology panels
From evidence to practice: Narrowing the gap
Dr Keith Fox talks to Drs Gregg Stone and Robert Harrington about why it takes so long for new evidence-based therapies to be adopted in clinical practice, the importance of national registries, and what can be done to make treatment guidelines more useful.
Genetic beta-blockade
What are the implications of an exciting discovery of intrinsic genetic beta-blockade common to 40% of people of African ancestry?

Dr Eric Topol invites you to share your opinions.

Click here to view the video blog and join the discussion.

HeartWire clips
On moving to industry: Interview with Dr Terry Ferguson
In conversation with heartwire news and features editor Larry Husten, Dr Terry Ferguson muses on changes to daily life, decision making processes, and patient care from a different perspective resulting from his new position in industry.
The Cardiology Show
Surrogate end points on trial: ENHANCE and other controversies
Part 2 is now live!
Nine of the world's top cardiologists gathered in Chicago to take on the issues raised by data released at the American College of Cardiology Scientific Sessions.

Dr Valentin Fuster moderates this frank and sometimes heated discussion on the results of ENHANCE, STRADIVARIUS, ONTARGET, and PERISCOPE, and the questions they raise about the responsibility of industry and the relevance of surrogate end points.
Forum
Smoking ban?
Read about our forum moderator's heroic and sometimes comic efforts to get a smoking ban passed by her city council in tobacco country.
Thumbs up, thumbs down
Controversies: ENHANCE and ACCORD
Clinical trials are under attack and in the headlines. What is the proper role of the investigators? What are the responsibilities of industry? Join Drs Eric J Topol and Robert M Califf in a discussion of the many issues surrounding ENHANCE and ACCORD.
Question
Do you think the ACC and SCAI should continue to combine their annual meetings in future years?
(See:Arranged marriage: Funding and "cultural differences" may dictate whether SCAI-ACC/i2 stay hitched)
No
Yes
Vote








Dyslipidemia  >  Mixed dyslipidemia
Mixed dyslipidemia: Attenuating risk... treatment beyond LDL
Mar 19, 2008 12:51 EDT / Join Drs Christie Ballantyne, Frank Sacks and Michael Davidson as they discuss the barriers to reaching target levels of all three key lipid components - LDL-C, HDL-C and triglycerides in the reduction of cardiovascular risk.
Steering Committee Members
Feb 27, 2008 14:09 EST / The CME programs of the Mixed Dyslipidemia Topic are under the medical direction of Drs Christie Ballantyne, Richard W Nesto, Michael Davidson and Frank Sacks.


CME provider: Medscape.
This educational activity is supported by an independent educational grant from Abbott Laboratories.
More on the Mixed Dyslipidemia clinical theme